False Hope: Bone Marrow Transplantation for Breast Cancer

Front Cover
Oxford University Press, USA, Jan 25, 2007 - Health & Fitness - 355 pages
In the late 1980s, a promising new treatment for breast cancer emerged: high-dose chemotherapy with autologous bone marrow transplantation or HDC/ABMT. By the 1990s, it had burst upon the oncology scene and disseminated rapidly before having been carefully evaluated. By the time published studies showed that the procedure was ineffective, more than 30,000 women had received the treatment, shortening their lives and adding to their suffering. This book tells of the rise and demise of HDC/ABMT for metastatic and early stage breast cancer, and fully explores the story's implications, which go well beyond the immediate procedure, and beyond breast cancer, to how we in the United States evaluate other medical procedures, especially life-saving ones.It details how the factors that drove clinical use--patient demand, physician enthusiasm, media reporting, litigation, economic exploitation, and legislative and administrative mandates--converged to propel the procedure forward despite a lack of proven clinical effectiveness. It also analyzes the limited effect of technology assessments before randomized clinical trials evaluated decisively the procedure and the ramifications of this system on healthcare today.Sections of the book consider the initial conditions surrounding the emergence of the new breast cancer treatment, the drivers of clinical use, and the struggle for evidence-based medicine. A concluding section considers the significance of the story for our healthcare system.

What people are saying - Write a review

User Review - Flag as inappropriate

My husband did the Response technologies impact center of Clearwater in 1997 and here we are doing good in 2020


Initial Conditions
Drivers of Clinical Use
The Struggle for EvidenceBased Medicine
The Significance of the Story
EvidenceBased Reviews of Clinical Trials

Other editions - View all

Common terms and phrases

About the author (2007)

Richard Rettig is an Adjunct Senior Social Scientist at RAND Corporation in Arlington, Virginia. Peter Jacobson is Director of the Center for Law, Ethics, and Health at the University of Michigan School of Public Health in Ann Arbor. Cynthia Farquhar is a Postgraduate Professor of Obstetricsand Gynaecology at the University of Auckland in New Zealand. Wade Aubry is an Associate Clinical Professor of Medicine at the UCSF Institute for Health Policy Studies.

Bibliographic information